173,842 research outputs found
Recommended from our members
Dora C. Mirabal and Aracelia Gonzelez Cervera
No full textBlack and White Photo Negative of Dora C. Mirabal and Aracelia Gonzelez Cervera (Dora's Mother)
Limenandra confusa Carmona, Pola, Gosliner & Cervera 2014
No full textLimenandra confusa Carmona, Pola, Gosliner & Cervera, 2014 (Figure 34 C) Material examined. One specimen. MB28-004710, ZRP, 0 8 Aug. 2013, 0.5m, 14mm. Habitats. Subtropical tidal reef. Occurrences. Zavora. Geographic distribution. Indo-west, central and eastern Pacific. Costa Rica (Camacho-García et al. 2005), Gulf of California (Bertsch 1972), Hawaii (Kay 1979), Midway Islands (Carmona et al. 2014c), Philippines, Mexico (Gosliner et al. 2008) and Mozambique. Remarks. The Mozambican specimen exhibited a synchronised movement of its longer mid-dorsal cerata whilst crawling, behaviour not previously reported. Carmona et al. (2014b) recently reviewed this genus. Limenadra nodosa occurs in the Mediterranean and Atlantic whilst L. confusa is distributed in the Pacific (Carmona et al. 2014c). As a result it is likely that this specimen represents the first record of L. confusa from the Indian Ocean.Published as part of Tibiriçá, Yara, Pola, Marta & Cervera, Juan Lucas, 2017, Astonishing diversity revealed: an annotated and illustrated inventory of Nudipleura (Gastropoda: Heterobranchia) from Mozambique, pp. 1-133 in Zootaxa 4359 (1) on page 108, DOI: 10.11646/zootaxa.4359.1.1, http://zenodo.org/record/106916
CERVERA, Gabriel R. (Gen.)
No full textCorrespondence of Brig. Gen. Gabriel R. Cervera, Mr. Porfirio García de León, Mr. José Molina, President of the House of Representatives, and Gen. Alvaro Obregón, concerning an election conflict due to the victory of the Mugiquista Party. (The Manifesto was transferred to archive 1, box 1, folder 1, Doc. 5). File C-47 / Correspondencia entre el Gral. Brig. Gabriel R. Cervera, los Srs. Porfirio García de León, José Molina, Presidente de la Cámara de Diputados y el Gral. Alvaro Obregón, relativa al conflicto electoral en Michoacán debido al triunfo del Partido Mugiquista. (El Manifiesto pasó al planero 1, cajón 1, carpeta 2, folder 5). Exp. C-4
Zona C y lo mejor del 2017
No full text¿Qué nos deja este 2017? La evolución del programa lo largo del año, conducido por docente Claudia Bayona, Angélica Naranjo, Paula Cervera y Paola Castill
Corrigendum to “Modelling of Bingham and Herschel-Bulkley flows with mixed P1/P1 finite elements stabilized with Orthogonal Subgrid Scale” [J. Nonnewt Fluid Mech, 228, 2016, p. 1–16]
No full textThis corrigendum provides some missing data and a reference for the paper Modelling of Bingham and Herschel-Bulkley flows with mixed P1/P1 finite elements stabilized with Orthogonal Subgrid Scale, as well as it corrects a mistaken unit of measure in the caption of a figure.
The authors apologise for the inconveniences caused.
Corrigendum
–
The caption of Figure 14 should read:
Cylinder in an Herschel-Bulkley fluid. Drag force coefficient in terms of the relation L:R for Bn∗ = 10.
–
The flow index n in the sub-captions of Figure 17(a)-17(l) is nondimensional.
–
The following Reference should be added: [71] E. Moreno, M. Cervera "Elementos finitos mixtos estabilizados para flujos confinados de Bingham y de Herschel-Bulkley Parte II: soluciones numéricas" Revista Internacional de Métodos Numéricos para Cálculo y Diseño en Ingeniería, 2016; 32(3); 131-138.
–
The captions of Figures 2, 4-7, 22-25 should include the following text at the end:
(Reproduced with permission from [71])
Diagnóstico ambiental del término municipal de Bonrepòs i Mirambell (Valencia). Propuesta de actuaciones hacia un desarrollo sostenible
No full textCervera Roig, C. (2010). Diagnóstico ambiental del término municipal de Bonrepòs i Mirambell (Valencia). Propuesta de actuaciones hacia un desarrollo sostenible. Universitat Politècnica de València. https://riunet.upv.es/handle/10251/15147Archivo delegad
Síndrome antifosfolipídico catastrófico
No full text[spa] INTRODUCCIÓN: El síndrome antifosfolipídico catastrófico fue descrito por Asherson en el año 1992 como una variante del síndrome antifosfolipídico (SAF) que conduce a insuficiencia multiorgánica, caracteriza por la oclusión trombótica de los vasos de pequeño calibre, que se produce en un breve período de tiempo en presencia de anticuerpos antifosfolipídicos. Representa aproximadamente el 1% de los pacientes con SAF, pero la mortalidad es mayor del 50%. Las causas y los factores pronósticos que influyen es esta elevada mortalidad son desconocidos.HIPÓTESIS: El SAF catastrófico debería ser considerado en el diagnóstico diferencial de los pacientes con fallo multiorgánico (FMO), síndrome de distrés respiratorio agudo (SDRA) y anenia hemolítica microangiopática (AHM). El esquema terapéutico combinando glucorticoides (GC) junto a anticoagulación efectiva (AC) y recambio plasmático (RP), sería es el que consigue mayores tasas de supervivencia. Por tanto, la utilización de esta triple terapia podría mejorar la evolución de estos pacientes.OBJETIVOS: Analizar las características clínica y biológicas de los pacientes con SAF catastrófico, especialmente en aquellos que desarrollan SDRA y AHM. Determinar las causas y los factores pronósticos que condicionan su elevada mortalidad como así también la influencia del tratamiento en la evolución de estos enfermos.MATERIAL Y MÉTODOS:Debido a la baja prevalencia del síndrome es imposible que un solo centro reúna un número de pacientes suficientes para realizar estudios de investigación, por lo que se creó un registro internacional denominado "CAPS registry" con el fin de reunir todos los pacientes con SAF catastrófico. El servicio de enfermedades autoimmnes del Hospital Clínico de Barcelona es el centro coordinador para la recepción de la información y los directores y doctorando de esta tesis son los responsables del diseño, confección y actualización del mismo. El registro está patrocinado por el Europeam Forum on Antiphospholipid Antibodies y se diseñó como un portal abierto de libre acceso a través de la siguiente dirección: www.med.ub.es /MIMMUN/FORUM/CAPS. HTM. TRABAJOS PUBLICADOS:1. Espinosa G, Bucciarelli S, Cervera R et al. Thrombotic hemolitic microangiopathic anaemia and antiphospholipid antibodies. Ann Reum Dis 2004; 63: 730-736 (IF 6,96). 46 pacientes con AHM y anticuerpos antifosfolipídicos (aFL) fueron revisados. La presentación clínica fué: síndrome hemolítico urémico (26%), SAF catastrófico (23%), purpura trombótica trombocitopénica (13%) y síndrome HELLP (4%). El 70 % de los pacientes que recibieron recambio plasmático se recuperaron. La mortalidad fué del 22%.2. Bucciarelli S, Espinosa G, Cervera R. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome.Ann Rheum Dis 2006; 65:81-86 (IF : 6,96). El 68 % de los pacientes tuvieron afectación pulmonar y en el 31% se manifestó como SDRA. El 70% de los pacientes en los que se dispuso de anatomía patológica presentaron microtrombosis.3. Bucciarelli S, Espinosa G, Cervera R et al. Mortality in the catastrophic antiphospholipid syndrome. Prognostic factors in a series of 250 patients. Arthritis Rheum 2006 (en prensa) (IF: 7,42) La mortalidad global fue del 44%. La principal causa de muerte fue la afectación neurológica (27,9%) seguida por la afectación cardiaca y las infecciones en un 19,8%. La presencia de lupus eritematoso sistémico se asoció a una mayor mortalidad. La mayor tasa de recuperación estuvo se obtuvo con la utilización de GC+AC+RP. La mortalidad disminuyó un 20% después del 2001 asociada a una mayor utilización de la terapia combinada con GC+AC+RP.CONCLUSIONES:El SAF catastrófico debe ser considerado en el diagnóstico diferencial de los pacientes con FMO, SDRA y AHM. El tratamiento combinado con AC+GC+RP debe ser considerada como terapia de primera línea en los pacientes con SAF catastrófico.[eng] "CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME"BACKGROUND: The term catastrophic antiphospholipid syndrome (APS) was proposed by Asherson in 1992 for defining an accelerated form of APS resulting in multiorgan failure, developed in a very short period of time. Although patients with catastrophic APS represent less than 1% of patients with APS, the mortality rate is more than 50%. The causes of this high mortality are still unknown.HYPOTHESES: The catastrophic APS would be considered as differential diagnosis among multiorgan dysfunction, thrombotic haemolytic microangiopathic anaemia and acute respiratory distress syndrome. A higher recovery rate would be associated with combined treatment with anticoagulation + corticosteroids + plasma exchange (AC+CS+PE). OBJECTIVES: to analyse the clinical and laboratory features of patients with catastrophic APS mainly in those patients who develop thrombotic miroangiopathic anaemia (THMA) and acute respiratory distress syndrome (ARDS). To assess the main causes of death and the prognostic factors that can influence mortality in patients with catastrophic APS.METHOD: We analysed the patients with catastrophic APS included in the "CAPS registry" in order to achieve the objectives.RESULTS: FIRST STUDY: 46 patients were reviewed with AMTH and aPL. The clinical presentations were: hemolytic-uremic syndrome (26%), catastrophic APS (23%), thrombotic thrombocytopenic purpura (13%), and HELLP syndrome (4%). Recovery occurred in 70% of episodes treated with Plasm Exchange. SECOND STUDY: Pulmonary involvement was reported in 68% patients with catastrophic APS and 31% of them were diagnosed as having ARDS. Microthromboses was present in 70% patients. THIRD STUDY: Death occurred in 44%. Cerebral involvement was considered the main cause of death (27.2%) followed by cardiac involvement and infection (19.8% one each). The presence of systemic lupus erythematosus was associated with a higher mortality. A higher recovery rate was associated with combined treatment with anticoagulation + corticosteroids + plasma exchange (AC+CS+PE) (77.8%). The mortality decreased 20% from 2001 associated with the higher use rate of combined treatment with AC+CS+PE and/or IVIg.CONCLUSIONS: The catastrophic APS should be considered as differential diagnosis among multiorgan dysfunction, thrombotic haemolytic microangiopathic anaemia and acute respiratory distress syndrome. The combined therapy with AC+CS+PE should be the first line of therapy in patients with catastrophic APS
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
A CRITICAL APPROACH OF THE CALCULATION PROCEDURES TO BE USED IN DIGESTIBILITY DETERMINATION OF FEED INGREDIENTS FOR RABBITS
No full text[EN] The effect of differences between tested ingredient and
basal diet dry matter content and the effect of premix inclusion on the
digestible nutrient content of tested feedstuffs are analysed. The
calculation procedures to be followed in digestibility evaluation assays of
feed ingredients far rabbits are also described by means of examples.
The impact of dry matter correction on the estimation of the digestible
nutrient content of tested ingredient increases with increasing of
differences between the dry matter content of basal diet and tested ingredient, and between the nutrient content of basal and test diet, and
with decreasing substitution rate, varying from 0.05% to 9%. Premix
correction increases the digestible nutrient content of tested ingredient
proportionally to the premix addition (calculated on dry matter basis) and
independently of the substitution rate and of the kind of feedstuff
evaluated. Nevertheless, the complete correction (both by dry matter
and premix) sometimes has a compensatory effect, when corrections
act in opposite way.[FR] Les auteurs ont analysé les conséquences des différences de
composition entre la matiere premiere testée et le régime de base
servant a l'étudier, ainsi que les effets de la prise en compte du taux
d'inclusion du prémix, dans l'estimation de la digestibilité des éléments
nutritifs de cette matiere premiere. La procédure de calcul qu'il convient
de suivre pour la mesure de la digestibilité d'une matiere premiere est
décrite a l'aide d'exemoles. L'effet de la correction pour la teneur en
matiere séche de la mutiere premiere étudiée est d'autant plus grand
que cette teneur s'éloigne de celle de l'aliment de base, ou que s'accroit
l'écart de teneurs en nutriments digestibles entre l'aliment de base et
l'aliment expérimental contenant la matiere premiere étudiée. L'effet de la correction pour la teneur en matiére seche s'accroit aussi avec la
réduction du taux d'incorporation de la matiere premiére étudiée. Selon
les situations, cette correction pour la teneur en matiere séche, a un
impact qui représente de 0,05% a 9% des teneurs en éléments
digestibles estimées. La correction liée a la prise en compte du prémix
(lorsqu'il est incorporé a taux fixe dans taus les régimes expérimentaux)
accroit la valeur de la digestibilité attribuée aux nutriments de la matiere
premiere étudiée, de maniere proportionnelle au taux d'incorporation de
ce prémix (calculé sur la base de la matiere seche), quel que soit le type
de matiere premiere ou le taux de substitution entre le régime de base
et la matiere premiere étudiée.. Toutefois, la correction complete
(matiere seche et prémix ensemble) a quelquefois un effet
compensateur, quand les corrections agissent de maniere opposée ..Villamide, M.; Maertens, L.; Cervera, C.; Perez, J.; Xiccato, G. (2001). A CRITICAL APPROACH OF THE CALCULATION PROCEDURES TO BE USED IN DIGESTIBILITY DETERMINATION OF FEED INGREDIENTS FOR RABBITS. World Rabbit Science. 9(1). https://doi.org/10.4995/wrs.2001.442SWORD9
Mitomycin C in highly myopic eyes - Author reply
No full textOphthalmology. 2005 Feb;112(2):208-18; discussion 219.
Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes.
Gambato C, Ghirlando A, Moretto E, Busato F, Midena E.
SourceRefractive Surgery Service and Antimetabolite Therapy Research Unit, Department of Ophthalmology, University of Padova, Padova, Italy.
Abstract
PURPOSE: To evaluate the role of topical mitomycin C in corneal wound healing (CWH) after photorefractive keratectomy (PRK) in highly myopic eyes.
DESIGN: Prospective, double-masked, randomized clinical trial.
PARTICIPANTS: Seventy-two eyes of 36 patients affected by high (>7 diopters) myopia.
METHODS: In each patient, one eye was randomly assigned to PRK with intraoperative topical 0.02% mitomycin C application, and the fellow eye was treated with a placebo. Postoperatively, mitomycin C-treated eyes received artificial tears (3 times daily, tapered in 3 months), whereas the fellow eye was treated with fluorometholone sodium 2% and artificial tears (3 times daily, tapered in 3 months).
MAIN OUTCOME MEASURES: Uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA), contrast sensitivity, manifest refraction, and biomicroscopy. Contrast sensitivity was determined using the Pelli-Robson chart. Corneal confocal microscopy documented CWH.
RESULTS: Mean follow-up was 18 months (range, 12-36). No side effects or toxic effects were documented. At 12-month follow-up examination, UCVAs (logarithm of the minimum angle of resolution) were 0.4+/-0.48 and 0.5+/-0.53 (P = .03) in mitomycin C-treated eyes and corticosteroid-treated eyes, respectively. At 1 year, corneal haze developed in 20% of corticosteroid-treated eyes, versus 0% of mitomycin C-treated eyes. At 12, 24, and 36 months, corneal confocal microscopy showed activated keratocytes and extracellular matrix significantly more evident in untreated eyes (Ps = 0.004, 0.024, and 0.046, respectively).
CONCLUSION: Topical intraoperative application of 0.02% mitomycin C can reduce haze formation in highly myopic eyes undergoing PRK.
Comment in
Ophthalmology. 2006 Feb;113(2):357; author reply 357-8
- …
